ROCKLAND, Mass. and NEW YORK, May 14, 2019 /PRNewswire/ -- BAVENCIO is the first anti-PD-L1 in combination with INLYTA approved by FDA for first-line treatment of patients with advanced renal
Growth Capitalist (https://growthcapitalist.com/2019/05/fda-approves-bavencio-avelumab-plus-inlyta-axitinib-combination-for-patients-with-advanced-renal-cell-carcinoma/)
ROCKLAND, Mass. and NEW YORK, May 14, 2019 /PRNewswire/ -- BAVENCIO is the first anti-PD-L1 in combination with INLYTA approved by FDA for first-line treatment of patients with advanced renal